Depo-Provera MDL vs Class Action: Status and Eligibility

Last Updated: July 16, 2026 | Reviewed by: Legal Lawsuit Editorial Team | Primary Sources: JPML MDL docket records, FDA drug safety communications.

Depo-Provera MDL vs. Class Action: Where the Depo Provera Class Action Lawsuit Stands

Searches for a Depo-Provera class action lawsuit reflect a major legal issue affecting thousands of women in the U.S. Here is an overview of where things stand: Litigation Snapshot:

• 435+ active cases had been consolidated in federal court (Northern District of Florida) early in the MDL, and the count has grown since
• Not a certified class action – each claim proceeds as an individual lawsuit inside a Multidistrict Litigation (MDL)
• Judge M. Casey Rodgers presides over the proceedings as MDL 3140
• Pfizer Inc. is the main defendant

Key Facts:

• Using Depo-Provera for more than a year has been associated with a 5.6-fold higher risk of meningioma
• The first suit was filed in October 2024 by a woman diagnosed with a brain tumor after 16 years on the shot
• Filings rose quickly, with one stretch showing an increase of nearly 25% in a single month

Women are suing Pfizer, alleging the company knew the injection was tied to brain tumors but did not warn patients and doctors in the U.S. The central dispute is whether Pfizer should have strengthened its U.S. warnings years ago, as it did in Canada and Europe. A March 2024 British Medical Journal study involving more than 18,000 women with meningioma offered strong evidence connecting long-term use to these tumors, bolstering the claims and prompting more women to come forward. I’m Mason Arnao. I help people make sense of complicated legal matters like the Depo-Provera litigation, and I have seen how it gives hope to women facing serious health problems linked to their birth control. My data analysis background helps me spot important patterns in pharmaceutical cases like this one.

More on the Depo-Provera lawsuit:

• Depo Provera severe side effects
• depo shot brain tumor

How Depo-Provera Is Linked to Meningioma Brain Tumors

Anyone who has used this medication and is following the Depo-Provera MDL should understand how a contraceptive shot could relate to brain tumors. Depo-Provera, or medroxyprogesterone acetate (MPA), is a long-acting injection given every three months that blocks ovulation and thickens cervical mucus; it is also used for endometriosis and certain cancer treatments. The concern involves how this synthetic hormone affects the body over time. Meningiomas are tumors that grow in the meninges, the protective membranes surrounding the brain and spinal cord. Most are benign, but benign does not mean harmless — as they enlarge, they can press on the brain and cause serious neurological problems. Critically, meningioma cells often carry many progesterone receptors, and repeated Depo-Provera shots expose the body to high levels of synthetic progestin that may feed these hormone-sensitive tumors.

The Scientific Evidence Behind the Claims

The connection is not a new discovery. Studies going back to the 1980s showed meningioma cells react to progesterone-like hormones, and the lawsuits argue that research should have alerted Pfizer to a potential problem. The March 2024 BMJ study drew on data from more than 108,000 women, including over 18,000 who had meningioma surgery. Its findings were striking: users of the drug had a 5.6-fold higher risk of meningiomas serious enough to require surgery, with the greatest risk among long-term users (over one year) — a clear sign that longer use meant higher risk. The study’s size and design accounted for how long tumors take to develop and found that other hormonal contraceptives did not carry the same risk, singling out Depo-Provera. Plaintiffs say this supports their position that Pfizer knew or should have known about the danger yet did not warn U.S. patients and doctors, even though labels in Canada and parts of Europe already mentioned brain tumors. Read more at Depo Shot Brain Tumor.

Warning Signs of a Meningioma

Meningioma symptoms can be hard to spot because they develop slowly. If you used Depo-Provera for a long time, learn the warning signs, which often start mildly and intensify as the tumor grows and presses on the brain. Typical symptoms include:

• Headaches that linger, get worse and do not ease with standard pain relievers.
• Vision problems such as blurry or double vision or blind spots.
• Seizures, sometimes for the first time.
• Hearing changes, including hearing loss in one ear or ringing (tinnitus).
• Memory trouble, from forgetfulness to difficulty learning new information.
• Weakness or numbness in the arms or legs, often on one side.
• Speech problems, such as slurring or struggling to find words.
• Shifts in personality or mood that loved ones may notice first.
• Loss of smell and balance issues such as dizziness.

An accurate diagnosis matters. If these symptoms are new or getting worse, see a doctor. MRI is the most reliable way to detect meningiomas, and early diagnosis improves treatment results while also providing key evidence for any legal claim.

Depo-Provera MDL vs. Class Action: The Current Litigation

The Depo-Provera litigation is a major pharmaceutical case. People often call it a Depo-Provera class action lawsuit, but legally it is a Multidistrict Litigation (MDL), which gathers many individual lawsuits before a single federal judge for efficiency. The distinction matters: in an MDL, your case stays individual, so your specific injuries and losses are considered, which can lead to a more tailored result than a class action. MDL 3140 is the official designation, centralized in the Northern District of Florida on February 7, 2025. Judge M. Casey Rodgers, who has extensive experience with complex drug litigation, oversaw 435+ active cases early on, and filings climbed quickly — at one point by about 25% in a month — as awareness of the brain tumor link spread. The main defendants are Pfizer Inc. and Pharmacia & Upjohn Company.

Regulatory Background and Earlier Litigation

Depo-Provera’s regulatory history helps explain today’s cases. The FDA approved it for contraception in 1992, and in 2004 required a boxed warning — its most serious — about loss of bone density. That issue led to a reported $2 million class settlement in Canada in 2021 over failure to warn. For the brain tumor claims, the key point is that Canada and the EU added meningioma warnings to their labels years ago, while plaintiffs say U.S. labeling did not include one during the period they used the drug. That forms the heart of the failure-to-warn theory: Pfizer allegedly understood the risk and warned patients abroad but not in the U.S. (Check the current FDA label, linked below, for the latest U.S. wording.) See more at Depo-Provera Lawsuits.

What is the status of the Depo-Provera MDL?

Although many people search for a Depo-Provera class action, the MDL format often works better for plaintiffs. Consolidation in MDL 3140 allows shared discovery and consistent rulings while keeping each claim separate. A major step is the selection of bellwether cases — test cases that help gauge how juries may react to the evidence against Pfizer. Five pilot cases were selected, with discovery scheduled from March 2025 to March 2026, and their outcomes are likely to shape settlement talks for everyone else. The litigation picked up speed after the first case was filed in October 2024, and filings have climbed steadily since. The pretrial discovery phase is pivotal because it involves reviewing Pfizer’s internal documents, which could show whether the company knew of the dangers and failed to warn U.S. women.

Who Qualifies for a Depo-Provera Lawsuit, and What Compensation Is Possible?

If you used Depo-Provera and later developed a meningioma, you may have a claim, and Legal Lawsuit can connect you with experienced attorneys in our network for a free, confidential case review. Eligibility generally involves a few key criteria. Typically that means using Depo-Provera for at least one year (four injections), though some cases with shorter use may be reviewed. A medically confirmed meningioma diagnosis, such as by MRI, is the foundation of the claim. Timing matters too: ideally the diagnosis came at least three years after the first shot, reflecting how long these tumors take to develop. Medical records are essential, documenting both your Depo-Provera use and your diagnosis. Stopping the drug years ago does not necessarily disqualify you, and an experienced attorney can tell you whether your circumstances fit.

Possible Damages and What Drives Case Value

A brain tumor diagnosis can be financially overwhelming. These lawsuits seek to hold Pfizer responsible and to secure the support injured women need.

• Medical costs are frequently the biggest category and can be very high, covering diagnosis, surgery, radiation, medication and long-term care.
• Lost income and earning ability cover pay lost during recovery and long-term effects that limit your ability to work.
• Pain and suffering address the physical and emotional toll, including anxiety, depression and fear.
• When a death occurs, relatives may bring wrongful death claims for funeral costs and other losses.

As of this update, Pfizer has signed a Master Settlement Agreement for eligible MDL 3140 claims (July 2026), but its payout tiers are confidential, so any specific per-case dollar range is speculation. Value will likely depend on tumor size and location, whether surgery or radiation was needed, lasting neurological effects, length of Depo-Provera use and the strength of medical documentation.

• Claims with the most serious harm: generally those involving brain surgery, permanent deficits or loss of the ability to work
• Moderate cases: $300,000 – $650,000
• Lower-severity cases: $150,000 – $300,000

Cases that required surgery typically carry more value. Learn more at Birth Control Shot Lawsuit.

Filing Deadlines for a Depo-Provera Lawsuit

Timing is crucial in injury claims. The statute of limitations sets the deadline to file, and missing it can forfeit your right to compensation regardless of the strength of your case. Deadlines differ widely by state, from about one to six years. The discovery rule frequently helps by starting the clock when you were diagnosed or could reasonably have connected your condition to Depo-Provera, rather than when you used the drug. Because these rules are complicated and state-specific, talking to an attorney promptly is essential so your deadline is identified and every filing happens on time, protecting your rights and your chance at compensation.

Depo-Provera Lawsuit FAQs

Questions are natural if you think you may have a Depo-Provera claim. Here are answers to the ones asked most often.

What is the central allegation against Pfizer?

The main claim is “failure to warn.” Plaintiffs say that had they known Depo-Provera could substantially raise their brain tumor risk, they would have chosen another contraceptive. They allege Pfizer knew of the meningioma link but did not tell U.S. patients and doctors, pointing to warnings Pfizer added in Canada and the European Union that U.S. labels lacked. Plaintiffs argue this shows profits were put ahead of patient safety.

What does it cost to bring a Depo-Provera lawsuit?

There is no upfront cost. Attorneys take these cases on contingency, so they are paid a percentage of any recovery only if the case succeeds, and you owe no attorney fees otherwise. That lets people pursue claims against companies like Pfizer without financial risk, and attorneys in the Legal Lawsuit network work on this basis.

Can I sue if I received a generic version of Depo-Provera?

Possibly, though the issue is complicated. Generic manufacturers have traditionally been shielded by “preemption” because they cannot change warning labels on their own. That is shifting: plaintiffs are increasingly pressing “innovator liability,” which can hold the original maker (Pfizer) responsible for warnings even when a generic was used, and California and some other states have been more open to this theory. Because the law differs by state, talk with an attorney, who can assess whether you still have a viable claim against Pfizer.

Next Steps If You Think You Have a Claim

If you were diagnosed with a meningioma after using Depo-Provera, it is understandable to feel confused or angry, and you are not alone. Research shows long-term use is associated with a 5.6-fold higher risk of meningioma, and that evidence is driving the litigation against Pfizer. If you believe you have a claim, take these steps:

1. Confirm the Diagnosis: Obtain medical confirmation, including MRI results and pathology reports if you had surgery.
2. Collect Records: Gather proof of your Depo-Provera use (prescriptions, pharmacy records) and documentation of your diagnosis and treatment (MRIs, surgical reports and more).
3. Track Financial Losses: Save medical bills, records of lost pay and other related costs.
4. Write Down Your Story: Record your symptom timeline, the dates you used Depo-Provera and how your life has been affected.

The most important step is to speak with an attorney experienced in pharmaceutical litigation. These cases are complex and state deadlines are strict, and a skilled lawyer can assess whether you fit the Depo-Provera MDL, explain how it works and make sure you file before your deadline runs out. Legal Lawsuit is a legal-information site that connects people in your situation with experienced attorneys in our network who handle complex drug cases. We know how stressful legal questions are while you are coping with a serious diagnosis, and a free, confidential case review is a no-obligation way to find out whether you have a claim and what compensation may be possible. Attorneys handle these cases on contingency, so there are no attorney fees unless you recover. You trusted Depo-Provera to be safe, and if inadequate warnings broke that trust, you deserve accountability and fair compensation. Find out if you qualify for a Depo-Provera Lawsuit today.